En Carta Diagnostics develops at-home molecular diagnostic tests combining lab-grade PCR accuracy with the simplicity of a rapid test, starting with Lyme disease and STIs.
| Date | Round | Amount |
|---|---|---|
| Jul 2026 | Seed En Carta Diagnostics raised a 3 million euro equity tranche led by Blue Forest Ventures as part of a 5 million euro first closing to bring its at-home molecular tests to market. | $3.3M |
| Jul 2026 | Grant En Carta Diagnostics also secured 2 million euros in non-dilutive financing from Bpifrance and other partners as part of its 5 million euro first closing. | $2.2M |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.